Home » Clinical Trials » Sickle cell disease » NCT03664830
NCT03664830

A Pilot Study To Evaluate The Safety And Feasibility of Hematopoietic Progenitor Cell Mobilization With Plerixafor as Part of a Gene Therapy Strategy in Sickle Cell Disease

Study Summary

The objective of this study is to investigate if up to two injections of plerixafor represent a safe and effective strategy to mobilize adequate numbers of CD34+ hematopoietic stem progenitor cells (HSPC) for autologous hematopoietic cell transplantation (HCT) in sickle cell disease (SCD) patients

Interested in this trial?

Submit an Inquiry

Interventions

PlerixaforDRUG
Up to two subcutaneous injections of plerixafor (starting dose level: 240 µg/kg/dose)

Study Locations

FacilityCityStateCountry
City of Hope Medical CenterDuarteCaliforniaUnited States

Official Trial Information

View on ClinicalTrials.gov

Data sourced from ClinicalTrials.gov. Last updated: May 29, 2026